New Israeli autoinjector reduces deaths from severe bleeding by delivering lifesaving treatment in under five minutes — transforming emergency care on battlefields, at roadside accidents, and in disaster zones.
In a study published in the peer-reviewed journal Injury, researchers led by Prof. Arik Eisenkraft and Prof. David Gertz of the Institute for Research in Military Medicine at the Hebrew University of Jerusalem, in collaboration with the Israel Defense Forces Medical Corps, demonstrated that the autoinjector delivers Tranexamic Acid (TXA) as effectively as traditional intravenous (IV) methods.
TXA is known to stabilize blood clots and reduce blood loss, significantly improving survival in trauma situations.
Severe bleeding remains the leading cause of preventable death in emergencies, yet standard IV administration can be slow and difficult in chaotic conditions. Studies show that for every 15-minute delay in TXA treatment, its effectiveness drops by 10 percent.